Biodesix’s blood tests for lung cancer to be used in India

BOULDER — Biodesix Inc.  a developer and manufacturer of blood-test kits for cancer diagnostics, has inked a deal in which Positive Bioscience in Mumbai, India, will make Biodesix’s liquid biopsy tests available to patients in India.

Financial terms of the deal were not disclosed.

Courtesy Biodesix

All testing will be performed at Biodesix’s certified laboratory in Boulder.

This is the third international agreement that Biodesix has announced this year; the company entered into a collaboration with Beijing-based Bioyong Industries in January and a distribution agreement with Progenetics of Israel in March.

Positive Bioscience will use Biodesix’s GeneStrat and VeriStrat liquid biopsy tests for non-small cell lung cancer.

Samarth Jain, chief executive of Positive Bioscience, said that every year, thousands of Indian patients will benefit.

“Through its industry-leading turnaround time, Biodesix’s tests will also accelerate time to treatment,” Jain said in a prepared statement.

The VeriStrat test is used to assess disease aggressiveness by characterizing host response to the tumor, classifying patients as either VeriStrat-Good or VeriStrat-Poor. The GeneStrat test is a blood-based genomic test for patients with lung cancer that can inform the use of targeted therapies.

David Brunel, Biodesix’s chief executive, said the tests enable rapid and high-quality test results within four days, much faster than the 10-to 14-day turnaround time for tissue-based testing.